CapsoVision (NASDAQ:CV) (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.
In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting. This platform integrates seamlessly with the CapsoCam capsule, allowing physicians to access endoscopy images and diagnostic reports remotely and collaborate more efficiently on case reviews. The combination of the CapsoCam Plus capsule and the CapsoCloud platform supports a patient-centric workflow and can help reduce turnaround times for gastroenterology practices.
Founded on principles of innovation in gastrointestinal imaging, CapsoVision operates from its headquarters in Rochester, Minnesota, and serves a broad customer base across the United States and select international markets through a network of direct sales representatives and distribution partners. Its products have obtained regulatory clearances in multiple regions, and the company continues to invest in clinical research and new product development aimed at enhancing patient comfort and diagnostic accuracy.
CapsoVision is led by a management team with deep expertise in medical device commercialization and gastroenterology products. Under their guidance, the company focuses on expanding its market presence, advancing regulatory approvals, and fostering strategic collaborations with healthcare providers to support adoption of capsule endoscopy as a minimally invasive alternative to traditional endoscopic procedures.
